



# NAoMe

National Audit of  
Metastatic Breast Cancer

NAoMe, Clinical Effectiveness Unit

Royal College of Surgeons of England  
38-43 Lincoln's Inn Fields  
London WC2A 3PE

E: [BreastCancerAudits@rcseng.ac.uk](mailto:BreastCancerAudits@rcseng.ac.uk)

T: 020 7869 6610

 [NAoMe\\_news](#)

## NAoMe Newsletter, Summer 2023

### Want to hear more?

The NAoMe is part of the National Cancer Audit Collaborating Centre (NATCAN). If you want to find out more about NATCAN visit our [new website](#). If you would like to receive regular updates send us an email [NATCAN@rcseng.ac.uk](mailto:NATCAN@rcseng.ac.uk)

### Explore the new website and hear from Dr David Dodwell, Clinical co-lead for NAoMe



The National Cancer Audit Collaborating Centre (NATCAN) website has been launched. Visit the web pages for [NAoMe](#), and our sister audit [NAoPri](#) – the National Audit of Primary Breast Cancer – to find out more about the audits, the team and key resources. The NAoMe will work closely with the NAoPri, and build on the previous work done by [the National Audit of Breast Cancer in Older Patients \(NABCOP\)](#).

Watch the interview with David Dodwell, clinical co-lead for NAoMe (Clinical Oncology), who talks about the challenges involved in gathering data on patients with metastatic breast cancer. Particularly for specific groups of patients who have the most difficult problems.

### Dr Mark Verrill, Clinical co-lead (Medical Oncology) for the NAoPri and NAoMe, commented...



“The commissioning and launch of the National Audits of Primary and Metastatic Breast Cancer (NAoPri and NAoMe), is an exciting initiative that **will undoubtedly help to drive improvements in the care we offer to patients with breast cancer across England and Wales.**”

All of us at the NAoPri and NAoMe look forward to working with breast cancer teams, patients and other stakeholders to **ensure we make the most of the opportunity** to conduct a national clinical audit focused on agreed areas of need identified in a scoping survey in 2023.”

### FAQ

#### What progress has NAoMe made?

Since 1st October 2022, we have been working to set up the NAoMe's governance and infrastructure, and put in place the project team, including Clinical Leads from the NABCOP team. We have conducted a scoping exercise to inform priorities for the audits, and are analysing the survey returns.

The first audit reports will be published in 2024. Follow us on twitter [@NAoMe\\_news](#). Email questions to [breastcanceraudits@rcseng.ac.uk](mailto:breastcanceraudits@rcseng.ac.uk)

Several NABCOP resources remain relevant to this new audit, and available online, particularly:

 [Fitness assessment tool for older patients](#)

 [Guide to the breast cancer pathway for older women](#)

#### Which patients will be included in the NAoMe?

All patients diagnosed with metastatic breast cancer from 1 January 2015 onwards, in NHS hospitals within England and Wales, will be eligible for inclusion. This includes patients diagnosed with metastatic breast cancer at initial presentation as well as those diagnosed with metastases after an initial non-metastatic breast cancer diagnosis i.e., at recurrence or progression.

#### How are patient data being collected?

Similar to the previous NABCOP audit, the NAoMe will wish to limit any additional demands on Trusts, and will not directly 'collect' clinical patient data. Instead, the audit will use existing sources of patient data routinely collected by national organisations in England and Wales. See [FAQ #7](#) on the website for the new National Cancer Audit Collaboration Centre (NATCAN). The NAoMe will publish a list of key data items (a minimum dataset) later in 2023.